Polar warming in the Mars thermosphere: Seasonal variations owing to changing insolation and dust distributions

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/94781/1/grl20448.pd

Mars Climate Database version 5

The Mars Climate Database (MCD) is a database of meteorological fields derived from General Circulation Model (GCM) numerical simulations [2,4] of the Martian atmosphere and validated using available observational data. The MCD includes complementary post-processing schemes such as high spatial resolution interpolation of environmental data and means of reconstructing the variability thereof. The GCM is developed at LMD (Laboratoire de Météorologie Dynamique, Paris, France) in collaboration with several teams in Europe: LATMOS (Laboratoire Atmosphères, Milieux, Observations Spatiales, Paris, France), the Open University (UK), the Oxford University (UK) and the Instituto de Astrofisica de Andalucia (Spain) with support from the European Space Agency (ESA) and the Centre National d'Etudes Spatiales (CNES). The MCD is freely distributed and intended to be useful and used in the framework of engineering applications as well as in the context of scientific studies which require accurate knowledge of the state of the Martian atmosphere. The Mars Climate Database (MCD) has over the years been distributed to more than 150 teams around the world. With the many improvements implemented in the GCM over the last few years, a new series of reference simulations have been run and compiled in a new version (version 5) of the Mars Climate Database, released in the first half of 2012

Modeling the martian atmosphere with the LMD global climate model

Introduction: For several years we have been developing a 3D Global Climate Model (GCM) for Mars derived from the models used on Earth for weather forecasting or climate changes studies [1]. The purpose of such a project is ambitious: we wish to build a 'Mars simulator' based only on physical equations, with no tailor-made forcing, but able to reproduce all the available observations of the Martian climate (temperatures, winds, but also clouds, dust, ices, chemical species, etc...). The GCM is constantly evolving, thanks to a contnuous collaboration between several teams based in France (LMD, SA), the UK (The Open University, University of Oxford) and Spain (Instituto de Astrofisica de Andalucia), and with the support of ESA and CNES. We are currently working on an improved version of the model. Several new parametrisation are included in the heart of the model (radiative transfer, surface and subsurface processes, dynamics) and the applications of the GCM are in contnuous development (Water, dust, CO2, radon cycles, photochemistry, thermosphere, ionosphere, etc...

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.

PurposeThe KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2-positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete response rate (44.4% v 55.7%; P = .016), but fewer grade 3 or greater and serious adverse events (AEs). Here, we present 3-year outcomes from KRISTINE.MethodsPatients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles. Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received adjuvant trastuzumab plus pertuzumab. Secondary end points included event-free survival (EFS), overall survival, patient-reported outcomes (measured from random assignment), and invasive disease-free survival (IDFS; measured from surgery).ResultsOf patients, 444 were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221). Median follow-up was 37 months. Risk of an EFS event was higher with TDM-1+P (hazard ratio [HR], 2.61 [95% CI, 1.36 to 4.98]) with more locoregional progression events before surgery (15 [6.7%] v 0). Risk of an IDFS event after surgery was similar between arms (HR, 1.11 [95% CI, 0.52 to 2.40]). Pathologic complete response was associated with a reduced risk of an IDFS event (HR, 0.24 [95% CI, 0.09 to 0.60]) regardless of treatment arm. Overall, grade 3 or greater AEs (31.8% v 67.7%) were less common with T-DM1+P. During adjuvant treatment, grade 3 or greater AEs (24.5% v 9.9%) and AEs leading to treatment discontinuation (18.4% v 3.8%) were more common with T-DM1+P. Patient-reported outcomes favored T-DM1+P during neoadjuvant treatment and were similar to trastuzumab plus pertuzumab during adjuvant treatment.ConclusionCompared with TCH+P, T-DM1+P resulted in a higher risk of an EFS event owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment

Martian Atmospheric Temperature and Density Profiles During the First Year of NOMAD/TGO Solar Occultation Measurements

We present vertical profiles of temperature and density from solar occultation (SO) observations by the “Nadir and Occultation for Mars Discovery” (NOMAD) spectrometer on board the Trace Gas Orbiter during its first operational year, which covered the second half of Mars Year 34. We used calibrated transmittance spectra in 380 scans, and apply an in-house pre-processing to clean data systematics. Temperature and CO2 profiles up to about 90 km, with consistent hydrostatic adjustment, are obtained, after adapting an Earth-tested retrieval scheme to Mars conditions. Both pre-processing and retrieval are discussed to illustrate their performance and robustness. Our results reveal the large impact of the MY34 Global Dust Storm (GDS), which warmed the atmosphere at all altitudes. The large GDS aerosols opacity limited the sounding of tropospheric layers. The retrieved temperatures agree well with global climate models (GCM) at tropospheric altitudes, but NOMAD mesospheric temperatures are wavier and globally colder by 10 K in the perihelion season, particularly during the GDS and its decay phase. We observe a warm layer around 80 km during the Southern Spring, especially in the Northern Hemisphere morning terminator, associated to large thermal tides, significantly stronger than in the GCM. Cold mesospheric pockets, close to CO2 condensation temperatures, are more frequently observed than in the GCM. NOMAD CO2 densities show oscillations upon a seasonal trend that track well the latitudinal variations expected. Results uncertainties and suggestions to improve future data re-analysis are briefly discussed

Solar cycle variability of Mars dayside exospheric temperatures: Model evaluation of underlying thermal balances

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/95086/1/grl25450.pd

Measurements of stratospheric constituents by ISAMS

ISAMS is a limb sounding radiometer flying on the UARS, and designed to measure temperature, pressure, O3, CO, NO, NO2, N2O5, HNO3, CH4, H2O, N2O, and aerosol. Its capabilities are described, together with the present status of validation of its data products, and plans for future improvement

Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial

Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level-1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4-26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3-4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months

The challenge and scientific application of the CO2 4.3 um atmospheric limb emission of Mars

The atmospheric fluorescent emissions of CO2 at 4.3- um have been observed in the daytime upper atmosphere of Mars from a limb geometry by the instruments OMEGA and PFS on board Mars Express [1, 8]. Initial analysis using non-local thermodynamic equilibrium (NLTE) models show that the emissions are well understood [7, 3, 6]. Yet they have not been exploited to derive important thermospheric parameters, like CO2 densities and temperatures. Our major goals are to improve current NLTE models with a joint study of OMEGA and PFS data, and to build an ambitious state-of-the-art NLTE retreival scheme for Mars. Recent progress has been made in these directions on Mars, Venus and Earth. We will present a summary of these efforts and the difficulties and expectatives for its application to the Mars Express dat